Search

Displaying results 1111 - 1120 of 3917 in total
  1. Drug

    Cilnidipine

    go.drugbank.com/drugs/DB09232
    Investigational

    Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium

  2. Drug

    Dihydrotachysterol

    go.drugbank.com/drugs/DB01070
    ApprovedWithdrawn

    A vitamin D that can be regarded as a reduction product of vitamin D2.

    Categories: Bone Density Conservation Agents
  3. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.

  4. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    Alpelisib was granted FDA approval on 24 May 2019.

  5. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed...

  6. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    [A230548] In February 2019, a black box warning for febuxostat was added, based on the findings of a post-market clinical study (the CARES trial) where there was an increased risk of cardiovascular … Febuxostat is a non-purine xanthine oxidase (XO) inhibitor.

  7. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    FDA approved on June 15, 2011. … The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis.

  8. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    [L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018.

  9. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    [L64052] It is used to identify tau NFT pathology in adults with cognitive impairment being evaluated for Alzheimer's disease and has not been established for evaluating non-Alzheimer's tauopathies. … L64052] After intravenous injection, florquinitau F 18 crosses the blood-brain barrier and accumulates in brain regions containing tau NFTs, allowing their distribution to be visualized and interpreted on

  10. Drug

    Propyphenazone

    go.drugbank.com/drugs/DB13524
    Investigational

    Propyphenazone is a non-steroidal anti-inflammatory agent with analgesic effects.[A275063, A275068]

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS